Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,716,882
  • Shares Outstanding, K 642,384
  • Annual Sales, $ 3,121 M
  • Annual Income, $ 1,137 M
  • EBIT $ 1,316 M
  • EBITDA $ 1,376 M
  • 60-Month Beta 0.90
  • Price/Sales 5.87
  • Price/Cash Flow 22.32
  • Price/Book 3.78

Options Overview Details

View History
  • Implied Volatility 40.91% (-3.69%)
  • Historical Volatility 38.15%
  • IV Percentile 16%
  • IV Rank 15.16%
  • IV High 93.64% on 02/12/25
  • IV Low 31.49% on 08/28/25
  • Expected Move (DTE 33) 2.98 (9.22%)
  • Put/Call Vol Ratio 1.51
  • Today's Volume 524
  • Volume Avg (30-Day) 356
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 6,795
  • Open Int (30-Day) 5,087
  • Expected Range 29.28 to 35.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.44
  • Number of Estimates 7
  • High Estimate 0.56
  • Low Estimate 0.35
  • Prior Year 0.57
  • Growth Rate Est. (year over year) -22.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.35 +6.26%
on 12/31/25
35.43 -8.98%
on 01/14/26
+0.90 (+2.87%)
since 12/16/25
3-Month
28.08 +14.85%
on 11/05/25
35.43 -8.98%
on 01/14/26
-0.50 (-1.53%)
since 10/16/25
52-Week
17.24 +87.06%
on 04/09/25
35.43 -8.98%
on 01/14/26
+11.03 (+51.98%)
since 01/16/25

Most Recent Stories

More News
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Company Announcement Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory...

GMAB : 32.25 (-4.73%)
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

Supports Genmab’s ambition to build an AI-enabled innovation model that advances the company’s vision of bringing transformative antibody medicines to patients

GMAB : 32.25 (-4.73%)
Genmab Portfolio Prioritization Update

Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review ...

GMAB : 32.25 (-4.73%)
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio ...

GMAB : 32.25 (-4.73%)
MRUS : 90.00 (-7.14%)
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option for...

GMAB : 32.25 (-4.73%)
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R 2 ) resulted in statistically significant and clinically...

GMAB : 32.25 (-4.73%)
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

New two- and three-year EPCORE ® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FL ...

GMAB : 32.25 (-4.73%)
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R 2 ) is the first and only bispecific-based...

GMAB : 32.25 (-4.73%)
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader...

GMAB : 32.25 (-4.73%)
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Merus N.V....

GMAB : 32.25 (-4.73%)
MRUS : 90.00 (-7.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 37.39
2nd Resistance Point 35.82
1st Resistance Point 34.03
Last Price 32.25
1st Support Level 30.67
2nd Support Level 29.10
3rd Support Level 27.31

See More

52-Week High 35.43
Last Price 32.25
Fibonacci 61.8% 28.48
Fibonacci 50% 26.33
Fibonacci 38.2% 24.19
52-Week Low 17.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar